EASL Podcasts: Recent Episodes
European Association for the Study of the Liver
The EASL Podcast collection includes educational podcasts and audio versions of digital EASL offerings. The ASK EASL Podcasts: Ongoing series of educational podcasts. EASL Studio: Your weekly hepatology broadcast news.
This episode questions whether assigning the label “ACLF” to a deteriorating patient truly alters clinical decisions, or if focusing on the specifics of organ failure and reversibility is more useful. Experts debate the real-world utility of prognostic scores, the clarity (or confusion) created by multiple definitions, and whether the ACLF concept drives urgency, facilitates transplant access, or improves outcomes. A thought-provoking look at where terminology meets bedside care.
Moderator: Tom Marjot
Speakers: Paolo Angeli and Julia Wendon
This EASL Studio is supported by GENFIT. EASL has received no input from GENFIT with regards to the content of this programme.
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
This EASL Studio explores the discrepancy between the huge burden of patients hospitalised with, and dying from, alcohol-related liver disease (ALD) or MetALD, versus the same disease’s near non-existence from population data. The panel will discuss whether current classification systems (heavily favoring metabolic causes) misrepresent the true burden of ALD and MetALD, and what clinicians can do to better map the role of alcohol in liver patients.
Moderator: Maja Thiele
Speakers: Brian Lee, Mzamo Mbelle, Elisa Pose
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?
Moderator: Ahmed Elsharkawy
Speakers: Ashley Brown, Tatyana Kushner and Sabela Lens
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
In hepatology, effective care goes beyond diagnostics and treatment. This episode explores the crucial questions hepatologists should ask to truly understand their patients’ needs, values, and priorities. By focusing on communication and patient-centred care, our experts highlight how listening carefully can improve adherence, enhance quality of life, and ultimately lead to better outcomes.
Moderator: Pierre-Emmanuel Rautou
Speakers: Agnès Dumas, Maria Hjorth, José Willemse, Zobair Younossi
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
This first session in a two-part EASL DeepDive series on the 2024 EASL-EASD-EASO MASLD Clinical Practice Guidelines will provide a detailed examination of the recommendations concerning diagnosis, non-invasive assessment, and risk stratification, with a view to supporting evidence-based clinical practice.
Learning objectives
- Have a good understanding of the concept/definition of MASLD within the framework of the new SLD nomenclature, including its contribution to disease progression in other diseases
- Get familiar with the role of non-invasive tests for risk stratification in MASLD, their pro- and cons, and how and in whom to use them for screening/case finding
- Get a detailed understanding of HCC risk and risk stratification in MASLD and the surveillance strategies to implement
This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and Novo Nordisk. Boehringer Ingelheim and Novo Nordisk have had no input in the selection and creation of this programme.
This episode addresses key challenges in vascular complications of liver disease, including the management of portal vein thrombosis (PVT) in patients with and without cirrhosis. Experts will explore controversies surrounding long-term anticoagulation therapy and discuss insights from the CIRROXABAN paper. Additionally, the episode will shed light on the management of splanchnic artery aneurysms, offering valuable guidance for clinical practice.
Moderator: Pierre-Emmanuel Rautou;
Faculty: Sarwa Darwish Murad, Juan-Carlos Garcia-Pagan, Valérie Vilgrain
Related episodes
- S4E11 – YI Choice: Gene therapy for liver disease — RNA interference and beyond
- S4E6 – Regenerating the liver graft with a machine?
- S3E11 – Regenerative Hepatology: From stem cells to tissue engineering
- S2E9 – YI Choice: Propelling liver cell biology into the third dimension
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
In this new edition of the EASL DeepDive, expert faculty guide participants through a focused and forward-looking discussion on key aspects of advanced MASLD, setting the stage for a deeper understanding of evolving clinical challenges and opportunities.
This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.
Learning objectives
- Understand the Pathophysiology: Describe the key pathophysiological mechanisms of MASLD and its progression to advanced liver disease and portal hypertension.
- Identify Unmet Clinical Needs: Recognise the current gaps in diagnosis, management, and treatment of advanced MASLD, highlighting the challenges of healthcare professionals in clinical practice.
- Evaluate Valuable Endpoints: Discuss the importance of selecting and utilising valuable clinical endpoints in managing MASLD to improve patient outcomes.
- Explore Emerging Therapies: Review the latest therapeutic strategies and potential interventions for advanced MASLD, focusing on how they address the unmet needs in patient care.
All EASL DeepDive are available on EASL Campus.
This EASL Studio episode explores state-of-the-art practices in diagnosing steatotic liver disease and stratifying patients effectively for targeted treatment in 2025. Focusing on integrating cardiometabolic risk profiling and dynamic alcohol consumption assessment, the discussion will discuss contemporary methods, frequency, and practical implementation in clinical settings to enhance precision medicine approaches.
Moderator: Aleksander Krag
Faculty: Meena Bansal, Mattias Ekstedt, Arun Sanyal
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
Listen to this EASL Studio episode to explore how artificial intelligence (AI) is transforming healthcare. Discuss its potential to revolutionise medical practice, its limitations, and whether it poses a threat or an opportunity for the future of the medical profession.
Moderator: Ahmed Elsharkawy
Faculty: Jakob Kather, Sabela Lens, Ashley Spann
Related episodes:
- EASL Studio at EASL Congress 2024 – Exploring new frontiers: The AI liver taskforce initiative
- S4E5 – AI for dummies
- S2E13 – Digital Pathology
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
With the release of the new HBV guidelines, treatment eligibility broadens. This EASL Studio explores how to communicate these changes, support shared decision-making, ensure adherence, and engage patients in ongoing care and clinical trials.
Moderator: Ahmed Elsharkawy
Faculty: Markus Cornberg, Sital Shah, Thomas Tu, Su Wang
This EASL Studio is supported by Aligos Therapeutics, GSK and Gilead Sciences Europe Ltd . EASL has received no input from Aligos Therapeutics, GSK or Gilead Sciences Europe Ltd with regards to the content of this programme.
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
Listen to this EASL Studio episode for insights on the new MASLD guidelines and their practical application. Hear from experts on navigating the nomenclature change, implementing guidelines in clinical workflows, and fostering behavioral change to improve patient outcomes across the care team.
Moderator: Sven Francque
Faculty: Marta Cervera, Elena George, Shelley Keating
This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and Madrigal Pharmaceuticals. Boehringer Ingelheim or Madrigal Pharmaceuticals have had no input in the selection and creation of this programme.
Related episode
- S5E5 – JHEP Live: The new nomenclature for SLD: A multidisciplinary evaluation and approach
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
This EASL Studio episode cuts through the noise to explore alcohol’s true impact on health and society, spotlighting patient stories, public misconceptions, and bold policy solutions from across Europe.
Moderator: David Barret (Internal Communications and Multimedia Manager, WHO Regional Office for Europe)
Faculty: Carina Ferreira-Borges (Regional Advisor for Alcohol, Illicit drugs and Prison health, WHO Regional Office for Europe), Aleksander Krag (EASL Secretary General), Hazel Martin (BBC Journalist and Liver Patient), Margarida Santos (General Practitioner Portugal), Riina Sikkut (Member of Estonian Parliament, former Minister of Health of Estonia)
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
What happens when hepatologists and interventional radiologists join forces? This episode discusses the power of collaboration – shared guidelines, joint training, and multidisciplinary care – to improve outcomes in complex liver disease.
Moderator: Sven Francque
Faculty: Irene Bargellini, Virginia Hernández-Gea, Max Seidensticker
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
Listen to this episode for a curated overview of landmark studies and breakthrough data presented at EASL Congress 2025, with expert insights on their clinical relevance and impact on the future of hepatology.
Moderator: Thomas Berg
Faculty: Hannes Hagström, Verena Keitel, Raj Mookerjee
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
Most liver diseases are diagnosed when it’s already too late. This episode explores the pros and cons of early screening, the gaps in current strategies, and how projects like LIVERAiM are aiming to change the game.
Moderator: Ahmed Elsharkawy
Faculty: Pere Ginès, Ian Rowe, Maja Thiele
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
In this fifth edition of the EASL DeepDive, join Christophe Bureau, Virginia Hernandez-Gea, Marika Rudler, and Manhal Izzy to gain expert insight into the selection, management, and outcomes of patients undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures.
This EASL DeepDive webinar is supported by W. L. Gore & Associates. W. L. Gore & Associates has had no input into the content of this EASL DeepDive.
Learning objectives
- Understand the criteria for selecting appropriate patients for Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures
- Learn to differentiate between high-risk and low-risk patients based on clinical indicators and patient history
- Explore the impact of cardiopulmonary conditions on the outcomes of TIPS procedures, and how/when to monitor for new-onset heart failure post TIPS
- Learn from Marika Rudler about the strategies for preventing and managing post-TIPS hepatic encephalopathy (HE)
- Discuss the latest research and treatments available for managing EH in TIPS patients
All EASL DeepDive are available on EASL Campus.
This EASL Studio episode discusses cutting-edge approaches for managing bleeding varices. Explore the evolution of endoscopic therapies, the role of interventional radiology, and decision-making for high-risk gastric varices. Gain insights into EUS-guided portal pressure assessment and its impact on tailoring treatment strategies.
Moderator: Debbie Shawcross
Faculty: Wim Laleman, David Patch
Related episode
- S6E14: Endohepatology: The endoscopic liver gold rush
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
In this EASL DeepDive held on 06 November 2024, Alice Turner, Pavel Strnad, and Nicola Brunetti discuss and explore the changing insights in the management of Alpha-1 Antitrypsin Deficiency.
Learning objectives:
- Learn more about the role of heterozygosity of alpha-1 as a risk factor for chronic liver disease, especially in the context of other causes such as MASLD or alcohol
- Get a better understanding of the extrahepatic manifestations and the need for a multi-disciplinary approach
- Learn more about screening: who to screen and how
- Discover the general unmet needs related to AAT, with an emphasis on awareness and timely diagnosis
This EASL DeepDive webinar is supported by Takeda Pharmaceuticals. Takeda Pharmaceuticals has had no input into the content of this EASL DeepDive.
Click here to see all EASL Video Podcasts on Apple Podcasts.
In this EASL DeepDive held on 03 July 2024, Palak Trivedi, Emma Culver, Andreas Kremer and Jessica Dyson explain the risk assessment in people with PBC as well as the mechanistic and treatment of fatigue and pruritus.
Learning objectives
- Discover the latest mechanistic insights relating to the occurrence of PBC symptoms
- Learn more about the holistic management of PBC symptoms, with a particular emphasis on fatigue and pruritus
- Learn more about the current treatment options, their efficacy and limitations
- Get a detailed understanding of the drugs in the pipeline for the near future
This EASL DeepDive webinar is supported by GSK and IPSEN. GSK and IPSEN have had no input into the content of this EASL DeepDive.
Click here to see all EASL Video Podcasts on Apple Podcasts.
In this EASL DeepDive held on 30 October 2024, Henning Grønbæk, Cyrielle Caussy, Mazen Noureddin and Frank Tacke provide an understanding of the role of glucagon and glucagon-receptors in physiology and in MASH patients. Additionally, they review key clinical trials and evaluate the integration of GLP-1 receptor agonists into current EASL-EASD-EASO clinical guidelines for practical patient management.
Learning objectives:
- Understand the role of glucagon and glucagon-receptor in normal physiology and disease.
- Understand the rationale of a combined dual GLP-1/GCG RA and its potential benefit compared to a GLP-1RA alone and thus gain insights into the mechanisms through which GLP-1 receptor agonists and GLP-1/GCG might affect liver pathology and metabolic regulation.
- Discuss and review key clinical trials and ongoing development programs.
- Evaluate how GLP-1RA can be integrated into current EASL-EASD-EASO CPGs, with a focus on practical applications and patient management strategies, giving potential guidance for future applications.
This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.
Click here to see all EASL Video Podcasts on Apple Podcasts.
In this EASL DeepDive held on 25 February 2025, Ana Lleo, Adriaan van der Meer, Gideon Hirschfield, and Bettina Hansen explore the future of primary biliary cholangitis (PBC) treatment. Discover the emerging therapies, current challenges and personalised approaches that are shaping the management of PBC.
Learning objectives
- Learn more about the molecular mechanisms underlying the disease and the potential targets for drug therapy
- Get a good understanding of the efficacy of the current drugs and the potential added value of the upcoming second line treatments for PBC and where to position these new treatments in the treatment landscape
- Learn more about the evolving concepts regarding the endpoints in clinical trials for PBC
- Get insights in the risk assessment of people living with PBC and criteria for second line therapy
This EASL DeepDive webinar is supported by Gilead. Gilead has had no input into the content of this EASL DeepDive.
Click here to see all EASL Video Podcasts on Apple Podcasts.
This episode celebrates 40 years of the Journal of Hepatology, EASL’s flagship journal.
Tune in to discover how far we’ve come—and what’s next for the journal.
Moderator: Thomas Berg
Faculty: Paolo Angeli, Annalisa Berzigotti, Rajiv Jalan, Vlad Ratziu, Frank Tacke and Jessica Zucman-Rossi
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
Rare liver tumors like combined HCC/CCA, fibrolamellar HCC, and haemangioendothelioma pose significant diagnostic and therapeutic challenges. In this episode, we explore the latest insights, controversies, and clinical approaches outlined in the new EASL position paper. Join us to uncover how these advancements can address key hurdles in managing these rare malignancies.
Read the position paper: Rare primary liver cancers: An EASL position paper
Moderator: Thomas Berg
Faculty: Ruben de Kleine and Henning Wege
Related episodes
- S6E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond
- S5E13: Basics in decision-making for liver cancer treatment
- S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
This episode of EASL Studio explores insights from the European Alcohol Health Alliance Symposium, hosted by the WHO Regional Office for Europe in collaboration with EASL. Topics include managing alcohol marketing strategies, addressing gaps in cancer-related labelling, and understanding the influence of social norms on adolescent alcohol consumption. Learn from successful alcohol policy implementations and discover how the WHO Playbook can empower advocates to protect children and reshape public health strategies for alcohol-related harm.
Moderator: Shira Zelber-Sagi
Faculty: Frank Murray, Catherine Paradis (WHO Europe) and Debbie Shawcross
Related episodes
- S7E5 Why does WHO engagement with Steatotic Liver Disease matter?
- S6E7 The impact of policy measure in preventing liver diseases: The Hepahealth II study
- EASL Studio live from EASL Congress 2023: The battle to reduce alcohol harms… EASL’s new policy
- S3E5 JHEP Live: Stigma and alcohol
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects men and women differently, yet sex-based differences remain poorly explored. In the week celebrating International Women’s Day, this EASL Studio episode debates the molecular, hormonal, and genetic mechanisms driving these disparities.
Moderator: Saskia van Mil
Faculty: Sara Della Torre and Münevver Demir
Related episode
- S4E9YI Choice:Gender equality in academics — reducing the gap
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
Tune into this EASL Studio episode to learn about the role of PET imaging in Wilson’s disease. Discover how PET advances understanding, supports treatment decisions, and enhances patient care in managing this rare liver disorder.
Moderator: Debbie Shawcross
Faculty: Aftab Ala, Zoe Mariño and Thomas Sandahl
This EASL Studio is supported by Orphalan and Univar Solutions.
EASL has received no input from Orphalan or Univar Solutions with regards to the content of this programme.
Related episodes
- S4E15: Diagnostic and therapeutic challenges in Wilson’s disease
- S4E7: Genetics in adult liver disease – missed opportunities?
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
Join this EASL Studio episode for a clinical perspective on advancing HCC care. Explore the realities of adjuvant therapies, emerging molecular targets, and strategies for curative conversion. Gain insights into practical innovations shaping the future and translating research into improved patient outcomes.
Moderator: Thomas Berg
Faculty: Tim Greten and Anna Saborowski
This EASL Studio is supported by Bayer.
EASL has received no input from Bayer with regards to the content of this programme.
Related episodes
- EASL Studio S5E13: Basics in decision-making for liver cancer treatment
- EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
- EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
- EASL Studio S6E9: Therapy hierarchy in HCC: A new kid on the block
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
Watch this EASL Studio to start navigating your research journey with essential tips on generating ideas, refining hypotheses, and crafting standout abstracts for EASL Congress. Discover how to choose the right journal, prepare a submission-ready manuscript, and boost your career visibility in hepatology.
Moderator: Thomas Marjot
Faculty: Marta Afonso, Emma Andersson and Paolo Angeli
Related episodes
- S4E20 – COST Actions: Opportunities for pan-European collaborations in liver diseases
- S4E14 – EASL-EF CLIF and EU Grants: Exploring novel mechanism and treatment of chronic liver failure
- S4E2 YI Choice – How to build consortia and registries
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
Discover the latest updates from the updated EASL Clinical Practice Guidelines on Hepatocellular Carcinoma (HCC). This episode explores key advancements, their impact on clinical practice, and how they will shape the future of HCC diagnosis, treatment, and management. Join our faculty as they break down the changes and provide practical insights for healthcare professionals.
Moderator: Thomas Berg
Faculty: Peter Galle, Josep Llovet and Lorenza Rimassa
Related episodes
- EASL Studio S6E4: World Cholangiocarcinoma Day: Highlighting Guidelines and Exploring the Horizon Beyond
- EASL Studio S6E9: Therapy Hierarchy in HCC: A New Kid on the Block
- EASL Studio S5E13: Basics in Decision-Making for Liver Cancer Treatment
- EASL Studio Live from EASL Congress 2024: Advances in Systemic Treatments in Liver Cancer
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
Join us for the season premiere of EASL Studio Season 8 as we unpack key insights from the Steatotic Liver Disease (SLD) Summit. Explore the evolving consensus on patient trajectories, advancements in ALD and MetALD treatment pathways, and the latest endpoint discussions. The episode also highlights a holistic approach to diagnosing and managing comorbidities and revisits the standard of care in light of breakthroughs in MASH treatments.
Moderator: Aleksander Krag
Faculty: Cyrielle Caussy, Sven Francque and Brian Lee
This EASL Studio is supported by Madrigal. EASL has received no input from Madrigal with regards to the content of this programme.
Related episodes
- S7E3 – The changing face of Steatotic Liver Disease: Navigating new opportunities and emerging challenges
- EASL Studio at the Congress 2024: SLD nomenclature: Need for refinement?
- EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
- EASL Studio from EASL Congress 2023 – Steatotic liver disease global consensus to change nomenclature
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
This EASL Studio showcases cutting-edge research elucidating the role of the liver in ageing and exploring its role as a regulator of health and longevity. In particular, the liver’s function in modulating systemic ageing, its ability to buffer genetic and metabolic disturbances, and its influence on the progression of age-related diseases is discussed. Last but not least, panelists provides new insights into potential therapeutic strategies aimed at promoting healthy ageing by targeting liver-specific mechanisms.
This episode is related to this study published in July 2024: Inhibition of IL-11 signalling extends mammalian healthspan and lifespan
Faculty:
- Rui Castro (Moderator)
- Anna Mae Diehl (Faculty)
- Celia Martinez-Jiménez (Faculty)
Related episode
- EASL Studio S7E8: Sarcopenia: Converting research findings into clinical practice – Are we doing enough?
All EASL Studio Podcasts are available on EASL Campus.
This EASL Studio episode examines the current relevance of Hepatic Encephalopathy (HE) and the roles of hepatologists and interventional radiologists in patient care. The discussion covers technical approaches, patient outcomes, and the expanding indications for TIPS.
Tune in to:
- Learn about the critical roles of hepatologists and radiologists in managing HE.
- Understand technical factors, including TIPS procedures and their application in modern hepatology.
- Explore the use of TIPS for aging patients, those with variceal bleeding, and major surgery candidates.
Faculty
- Virginia Hernández-Gea (Moderator)
- Dominique Thabut (Faculty)
- Dhiraj Tripathi (Faculty)
- Thomas Kröncke (Faculty)
This EASL Studio is supported by an educational grant from Cook Medical. EASL has received no input from Cook Medical with regards to the content of this programme.
Related episodes
- EASL Studio S6E11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?
- EASL Studio S2E14: Elastography – The new non-invasive gold standard in portal hypertension?
All EASL Studio Podcasts are available on EASL Campus.
Sarcopenia, defined by a reduction in muscle mass and strength, significantly increases the risk of hospitalisation and mortality in patients with liver cirrhosis. This EASL Studio episode highlights the importance of incorporating sarcopenia assessment and management into routine clinical practice. Experts discuss the optimal timing for assessment and strategies for implementing effective interventions.
Faculty
- Felicity Williams (Moderator)
- Shelley Keating (Faculty)
- Jennifer Lai (Faculty)
- Jonathan Stine (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
This EASL Studio episode explores how alcohol worsens liver disease in patients with cardiometabolic risks, the stigma affecting diagnosis and care, and the latest therapeutic advances.
Key topics of discussion include:
- Interaction between alcohol and cardiometabolic risks
- Stigma and its impact on patient care
- Identifying at-risk patients with clinical markers
- Emerging therapies and research opportunities
Faculty
- Aleksander Krag (Moderator)
- Fredrik Åberg (Faculty)
- Maru Rinella (Faculty)
- Maja Thiele (Faculty)
This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.
Related episodes
- EASL Studio S5E9: Alcohol and the new nomenclature – A game-changer?
- EASL Studio S4E8: The central role of alcohol and food policies on liver health
- EASL Studio S4E3: A 360 approach to beat alcohol-related liver disease
- EASL Studio S3E5: JHEP Live: Stigma and alcohol
All EASL Studio Podcasts are available on EASL Campus.
Join the experts as they explore the new updates to the liver transplantation clinical practice guidelines, and delve into the latest advancement and ongoing challenges faced in this field.
Tune in to:
- Discover cutting-edge techniques like machine perfusion and extended criteria grafts.
- Learn about new transplant indications, including oncology and acute liver failure.
- Understand challenges in immunosuppression and the management of chronic rejection.
Faculty
- Ahmed Elsharkawy (Moderator)
- Didier Samuel (Faculty)
- Julie Heimbach (Faculty)
- Sarwa Darwish (Faculty)
Related episodes
- EASL Studio S4E13: JHEP Live: Liver transplantation for alcohol-related hepatitis
- EASL Studio S4E6: Regenerating the liver graft with a machine
- EASL Studio S3E2: Liver transplantation for ACLF: Opportunities, challenges, and pitfalls
- EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?
All EASL Studio Podcasts are available on EASL Campus.
This episode is organised in collaboration with the Healthy Livers, Healthy Lives Coalition.
Faculty
- Jeffrey Lazarus (Moderator)
- Mazen Noureddin (Faculty)
- Shira Zelber-Sagi (Faculty)
- Kremlin Wickramasinghe (Faculty)
The Healthy Livers, Healthy Lives Coalition’s activities are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk.
Our industry partners have had no input into the content of the Health Livers, Healthy Lives Coalition’s activities or this EASL Studio episode.
Related episodes
- EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
- EASL Studio S6E7: The impact of policy measure in preventing liver diseases: The Hepahealth II study
- EASL Studio S6E1: Do we solve MASLD by treating obesity?
- EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways
- EASL Studio S4 Special Edition 2: Promoting Liver Health: An urgent call for action at WHO
- EASL Studio S4E8: The central role of alcohol and food policies on liver health
All EASL Studio Podcasts are available on EASL Campus.
This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:
- Compares traditional ultrasound with advanced imaging techniques.
- Examines AI-based approaches in patient classification.
The episode concludes with a forward-looking perspective on the future management of MASLD.
Faculty
- Thomas Berg (Moderator)
- Timm Denecke (Faculty)
- Juan-Manuel Pericàs (Faculty)
- Valérie Vilgrain (Faculty)
This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.
Related episodes
- EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
- EASL Studio S6E1: Do we solve MASLD by treating obesity?
- EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
All EASL Studio Podcasts are available on EASL Campus.
Renal dysfunction is a significant concern for patients with liver cirrhosis, affecting nearly 50% of those hospitalised and leading to various complications that can reduce survival rates. Recently, the diagnostic criteria for acute kidney injury (AKI) and hepatorenal syndrome (HRS) have been updated to better capture the diversity and incidence of these conditions in cirrhotic patients.
This episode of EASL Studio:
- Explores the updated definitions and standardisation of AKI in the context of cirrhosis.
- Reviews recent clinical trials, including ATTIRE and CONFIRM, and their implications for patient care.
- Provides a critical analysis of current and emerging strategies for managing renal dysfunction in cirrhosis.
Faculty
- Debbie Shawcross (Moderator)
- Pere Gines (Faculty)
- Salvatore Piano (Faculty)
- Florence Wong (Faculty)
Related episodes
- EASL Studio from EASL Congress 2024: Deciphering the drivers of cirrhosis decompensation: Opportunities for intervention and prevention
- EASL Studio S6E8: Is there a role for measuring blood ammonia in patients with cirrhosis?
- EASL Studio S6E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?
- EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?
- EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
- EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?
All EASL Studio Podcasts are available on EASL Campus.
EASL Studio - Buongiorno Milano: What not to miss during EASL Congress.
Faculty
- Aleksander Krag (Moderator)
- Debbie Shawcross (Faculty)
- Thomas Berg (Faculty)
- Ahmed Elsharkawy (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
EASL Studio - Advances in systemic treatments in liver cancer
Faculty
- Josep Llovet (Moderator)
- Massimo Iavarone (Faculty)
- Matthias Pinter (Faculty)
- Jessica Zucman-Rossi (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
EASL Studio - Exploring new frontiers: The AI liver taskforce initiative
Faculty
- Eric Trépo (Moderator)
- Tom Lüdde (Faculty)
- Jakob Kather (Faculty)
- Raquel Pérez-López (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
EASL Studio - SLD nomenclature: Need for refinement?
Faculty
- Aleksander Krag (Moderator)
- Meena Bansal (Faculty)
- Sven Francque (Faculty)
- Alexandre Louvet (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
EASL Studio - Landmark studies at the EASL Congress 2024
Faculty
- Thomas Berg (Moderator)
- Rajiv Jalan (Faculty)
- Verena Keitel (Faculty)
- Frank Tacke (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
EASL Studio - Education at the heart of EASL’s mission
Faculty
- Sven Francque (Moderator)
- Krista Rombouts (Faculty)
- Rajeshwar Mookerjee (Faculty)
- Henning Grønbæk (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Arrivederci Milano, hallo Amsterdam!
Faculty
- Aleksander Krag (Moderator)
- Debbie Shawcross (Moderator)
- Cyrielle Caussy (Faculty)
- Ana Lleo (Faculty)
- Francesco Negro (Faculty)
- Vlad Ratziu (Faculty)
- Virginia Hernández-Gea (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
This session covers a wide range of topics relevant to the current landscape of viral hepatitis, including elimination efforts, resistance to direct-acting antivirals (DAAs), surveillance methods during and after therapy. This talk provides you with valuable insights through an up-to-date overview of the latest developments and challenges in the field.
Faculty
- Thomas Berg (Moderator)
- Jordan Feld (Faculty)
- Norah Terrault (Faculty)
- Heiner Wedemeyer (Faculty)
This episode is scheduled in honour of the United States’ Viral Hepatitis Awareness Month.
This EASL Studio is supported by GSK and Vir Biotechnology. EASL has received no input from GSK or Vir Biotechnology with regards to the content of this programme.
Related episodes
- Season 6, Episode 2: Why do we need HBV functional cure?
- Season 5, Episode 8: JHEP Live: Hepatitis Delta’s Latest Debate: Updates Straight from EASL’s Slate
- Season 5, Episode 3: Zoonotic Hepatitis E: What’s hot in 2023?
- EASL Studio at the EASL Congress 2023: The bumpy road of Hepatitis B drug development successes and challenges
- Season 4, Episode 19: HDV: The devil becomes treatable
- Season 4, Episode 1: Hepatitis B elimination: how far behind are we and what do we need to change to achieve it?
All EASL Studio Podcasts are available on EASL Campus.
This insightful discussion is centred on the burgeoning field of endohepatology, where advanced endoscopic techniques revolutionise hepatology practice. With this episode, explore the broad scope of endoscopic procedures (including EUS-guided liver biopsy, portal pressure measurement, and gastric varices embolisation) and their transformative impact on diagnostics and therapeutic interventions in liver disease.
To learn even more about endoscopic procedures in hepatology, take a look at this study by Wim Laleman et al., published in January 2024 in the Journal of Hepatology.
Faculty
- Wim Laleman (Moderator)
- Andres Cardenas (Faculty)
- Gavin Johnson (Faculty)
- Reem Sharaiha (Faculty)
Related episodes
- Season 6, Episode 11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?
- Season 3, Episode 15: Chronic portal vein thrombosis: anticoagulation and interventional radiology for all patients?
- Season 2, Episode 14: Elastography – The new non-invasive gold standard in portal hypertension?
All EASL Studio Podcasts are available on EASL Campus.
This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.
Faculty
- Aleksander Krag (Moderator)
- Naim Alkhouri (Faculty)
- Sven Francque (Faculty)
- Amalia Gastaldelli (Faculty)
Related episodes
- Season 5 , Episode 2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways
- EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
- Season 4, Episode 23: The Conundrum of NASH: The Growing Global Disease Burden with Low Disease Awareness
- Season 4, Episode 22: JHEP Live: New and promising drugs for NASH on the horizon
All EASL Studio Podcasts are available on EASL Campus.
Join us for a critical discussion on the significance of Drug and Herbal & Dietary Supplement-Induced Liver Injury (DHILI). In this episode, the speakers explore the importance of DHILI, assess recent advancements, and deliberate on the obstacles hindering further progress in addressing this pressing healthcare concern.
This episode is organised in collaboration with the EASL DHILI Consortium.
Faculty
- Guruprasad Padur Aithal (Moderator)
- Paul Hayashi (Faculty)
- Maribel Lucena (Faculty)
- Paul Watkins (Faculty)
Related episodes
- Season 4, Episode 20 – COST Actions: opportunities for pan-European collaborations in liver diseases
All EASL Studio Podcasts are available on EASL Campus.
In this episode, experts explore the shift away from invasive measurements in assessing clinically significant portal hypertension. The speakers address the crucial data needed to enhance the reliability and applicability of these non-invasive methods and introduce several advanced elastography techniques, shaping the future of portal hypertension assessment.
Faculty
- Bogdan Procopet (Moderator)
- Maria Papp (Faculty)
- Atoosa Rabiee (Faculty)
- Thomas Reiberger (Faculty)
Related episode
- EASL Studio S2E14: Elastography – The new non-invasive gold standard in portal hypertension?
All EASL Studio Podcasts are available on EASL Campus.
This episode aims at highlighting the importance of patient and public involvement in research. More precisely, the speakers focus on the importance of involving patients in research, practical steps to involve patients in research, and insights from EASL including engagement of patients in the EASL-Lancet Commission.
Faculty
- Marta Alonso-Peña (Moderator)
- Kate Jack (Faculty)
- Marko Korenjak (Faculty)
- Thomas Marjot (Faculty)
Related episode
- EASL Studio from EASL Congress 2023: United we stand: Global societies collaborating to beat liver disease.
All EASL Studio Podcasts are available on EASL Campus.
This episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion covers the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm.
Faculty
- Bruno Sangro (Moderator)
- Umberto Cillo (Faculty)
- Helen Reeves (Faculty)
- María Reig (Faculty)
This EASL Studio is supported by AstraZeneca. EASL has received no input from AstraZeneca with regards to the content of this programme.
Related episodes
- EASL Studio S5E13: Basics in decision-making for liver cancer treatment
- EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
- EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
- EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
- EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
- EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?
- EASL Studio S2E15: JHEP Live on the best animal model for HCC – Lost in translation?
All EASL Studio Podcasts are available on EASL Campus.
In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.
Faculty
- Debbie Shawcross (Moderator)
- Rajiv Jalan (Faculty)
- Sara Montagnese (Faculty)
- Elliot Tapper (Faculty)
This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).
Related episodes
- EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?
- EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
- EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?
- EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within
- EASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?
- EASL Studio S2E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?
All EASL Studio Podcasts are available on EASL Campus.
This episode treats of the Hepahealth II study, which aimed at estimating the impact of policy interventions targeting alcohol and obesity on the incidence of chronic liver disease and primary liver cancer in three European countries. Join our experts in their discussion of this study and of its conclusions.
Faculty
- Patrizia Burra (Moderator)
- Maria Buti (Faculty)
- Peter Jepsen (Faculty)
- Shira Zelber-Sagi (Faculty)
Related episodes
- EASL Studio S6E1: Do we solve MASLD by treating obesity?
- EASL Studio from EASL Congress 2023: The battle to reduce alcohol harms… EASL’s new policy
- EASL Studio S4E8: The central role of alcohol and food policies on liver health
- EASL Studio S2E2: Fats or carbs, who is the real villain?
All EASL Studio Podcasts are available on EASL Campus.
On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field.
Faculty
- Aleksander Krag (Moderator)
- Aftab Ala (Faculty)
- Pavel Strnad (Faculty)
- Alice Turner (Faculty)
Related episodes
- EASL Studio from EASL Congress 2023: Clinical trials in rare diseases – opportunities and challenges
- EASL Studio from ILC 2022: Rare Liver Diseases – A growing landscape of opportunities and challenges
This episode is scheduled in honour of the Rare Disease Day (29 February).
All EASL Studio Podcasts are available on EASL Campus.
The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research?
Faculty
- Paolo Angeli (Moderator)
- Guadalupe Garcia-Tsao (Faculty)
- Valérie Paradis (Faculty)
- Thomas Reiberger (Faculty)
Related episodes
- EASL Studio S5E5: JHEP Live: the new nomenclature for SLD: a multidisciplinary evaluation and approach
- EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
- EASL Studio S4E4: JHEP Live: Is the term ‘decompensated cirrhosis’ outdated?
All EASL Studio Podcasts are available on EASL Campus.
In this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead.
Faculty
- Thomas Berg (Moderator)
- Katie Kelley (Faculty)
- Daniela Sia (Faculty)
- Juan Valle (Faculty)
This episode is scheduled in honour of the World CCA Day (15 February) and the US CCA Awareness Month.
Related episodes
- EASL Studio S5E13: Basics in decision-making for liver cancer treatment
- EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
- EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
- EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
- EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
- EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?
All EASL Studio Podcasts are available on EASL Campus.
The participants focus on the topic of managing recurrent bleeding due to small-intestinal angiodysplasia – a persistent challenge encountered by many hepatologists. Our panel explores effective treatments and interventions, including medications like bevacizumab and thalidomide, alongside the role of endoscopy in diagnosis and management.
Faculty
- Pierre-Emmanuel Rautou (Moderator)
- Virginia Hernández-Gea (Faculty)
- Patrick Kamath (Faculty)
- Wim Laleman (Faculty)
Related episodes:
- EASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome
All EASL Studio Podcasts are available on EASL Campus.
Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists.
Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management!
Faculty
- Sven Francque (Moderator)
- Willem Pieter Brouwer (Faculty)
- Cyrielle Caussy (Faculty)
- Dimitris Papamargaritis (Faculty)
This episode is scheduled following the United Kingdom’s National Obesity Awareness Week.
Related episodes:
- EASL Studio S5E7: Why bother with diet and exercise when an injection will suffice?
- EASL Studio S4E8: The central role of alcohol and food policies on liver health
- EASL Studio S2E2: Fats or carbs, who is the real villain?
All EASL Studio Podcasts are available on EASL Campus.
Join us for a wrap-up of EASL Studio’s season and a preview of what is to come in 2024! In this special episode, we reminisce about the year’s top hepatology breakthroughs and controversies. This festive discussion highlights the best of the past while offering an exciting glimpse into the future of the evolving world of liver health.
Faculty
- Aleksander Krag (Moderator)
- Thomas Berg (Faculty)
- Ahmed Elsharkawy (Faculty)
- Debbie Shawcross (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Hepatic encephalopathy (HE) is a common reversible complication of advanced liver disease characterised by a spectrum of neuropsychiatric abnormalities. Due to its insidious onset, most patients only seek treatment once complications develop, resulting in it being an underdiagnosed and underestimated condition.
This EASL Studio episode, organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN), explores the patient journey and treatment options.
Faculty
- Debbie Shawcross (Moderator)
- Christian Labenz (Faculty)
- Steve Rodrigues (Faculty)
- Dominique Thabut (Faculty)
This EASL Studio is supported by Norgine. EASL has received no input from Norgine with regards to the content of this programme.
Related episode
- EASL Studio S2E7: JHEP Live on critical appraisal of classification, diagnosis and treatment of hepatic encephalopathy
All EASL Studio Podcasts are available on EASL Campus.
With cases of hepatocellular carcinoma on the rise and representing the end stage of many chronic liver diseases, the treatment of liver cancer has become one of the most dynamic areas in hepatology. The focus of this episode is on answering practical clinical questions, examining trial data, and sharing clinical insights that may be useful for decision-making in daily clinical practice.
Faculty
- Tom Lüdde (Moderator)
- Christoph Roderburg (Faculty)
- Anna Saborowski (Faculty)
- Arndt Vogel (Faculty)
This EASL Studio is supported by AstraZeneca and Eisai. EASL has received no input from AstraZeneca or Eisai with regards to the content of this programme.
Related episodes
- EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
- EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
- EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
- EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
- EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?
All EASL Studio Podcasts are available on EASL Campus.
This episode explores key aspects of intriguing intersection of autoimmune liver diseases, such as their distinctive presentations in childhood and adulthood and the influence of inflammatory bowel disease on liver disease phenotypes. The speakers also examines the benefits and risks associated with immunosuppressive treatments in managing these complex conditions.
Faculty
- Palak Trivedi (Moderator)
- Amanda Ricciuto (Faculty)
- Marianne Samyn (Faculty)
- Christoph Schramm (Faculty)
This EASL Studio is supported by Chemomab Therapeutics. EASL has received no input from Chemomab Therapeutics with regards to the content of this programme.
Related episodes
- EASL Studio S5E4: PBC: the itch we need to scratch
- EASL Studio from EASL Congress 2023: Challenges and opportunities for patients with PBC: Highlights from EASL Congress 2023
- EASL Studio S3E3: Primary biliary cholangitis: a look at the future landscape of therapy for patients
All EASL Studio Podcasts are available on EASL Campus.
The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis.
Faculty
- Thomas Reiberger (Moderator)
- Juan Gonzalez-Abraldes (Faculty)
- Elisa Pose (Faculty)
- Jonel Trebicka (Faculty)
This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.
Related episodes
- EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
- EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?
- EASL Studio S4E4: JHEP Live: is the term ‘decompensated cirrhosis’ outdated?
- EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within
All EASL Studio Podcasts are available on EASL Campus.
In this episode, participants tackle the relationship between metabolic dysfunction-associated steatotic liver diseases (MASLD) and type 2 diabetes (T2D), exploring their prevalence and the potential for more aggressive outcomes. Experts weigh in on the pressing questions of whether non-invasive test thresholds should be adapted for MASLD patients with T2D and which drugs should take precedence as first-line treatments for high-risk MASLD cases.
Faculty
- Zobair Younossi (Moderator)
- Laurent Castera (Faculty)
- Camilla Dalby Hansen (Faculty)
- Amalia Gastaldelli (Faculty)
This episode is scheduled according to the international calendar for the World Diabetes Day (14 November).
This EASL Studio is supported by Boehringer Ingelheim and Novo Nordisk. EASL has received no input from Boehringer Ingelheim or Novo Nordisk with regards to the content of this programme.
Related episodes:
- EASL Studio S3E7: Bugs and the liver — the role of the gut microbiome in liver diseases
- EASL Studio S2E2: Fats or carbs, who is the real villain?
All EASL Studio Podcasts are available on EASL Campus.
In honour of the Awareness Week on Alcohol related harm (21 November – 1 December), this episode discussed how the new nomenclature will affect healthcare pathways for those suffering with Alcohol-related liver diseases.
Faculty
- Aleksander Krag (Moderator)
- Juan Pablo Arab (Faculty)
- Alexandre Louvet (Faculty)
- Maru Rinella (Faculty)
Related episodes:
- EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
- EASL Studio S4E8: The central role of alcohol and food policies on liver health
- EASL Studio S3E5: JHEP Live: Stigma and alcohol
All EASL Studio Podcasts are available on EASL Campus.
Join the faculty as they take a deep dive into hepatitis delta (HDV) to:
- Shed light on the controversies surrounding this disease.
- Share their perspectives on the latest and most hotly debated recommendations.
- Discuss how these new recommendations will shape the future of research and patient care.
Faculty
- Thomas Berg (Moderator)
- Maurizia Brunetto (Faculty)
- Ohad Etzion (Faculty)
Related episodes:
- EASL Studio S2E3: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitor
- EASL Studio S2E8: Treatment of HBV-HDV coinfection in the era of entry inhibition
All EASL Studio Podcasts are available on EASL Campus.
During this episode, the experts discuss of what it really takes to implement a successful lifestyle modification in behavioural therapy. Tune in to learn tools and tips that can help treat patients in improving their liver health and quality of life.
This episode was scheduled according to the international calendar for the World Food Day (16 October)
Faculty
- Shira Zelber Sagi (Moderator)
- Riccardo Dalle Grave (Faculty)
- Giulio Marchesini (Faculty)
Related episodes
- EASL Studio S4E8: The central role of alcohol and food policies on liver health
- EASL Studio S2E2: Fats or carbs, who is the real villain?
All EASL Studio Podcasts are available on EASL Campus.
This episode delves into the pervasive yet seldom-discussed issue of burnout, particularly prevalent in high-pressure fields like clinical medicine and competitive research.
Fuelled by relentless ambition and a fear of falling short, professionals push themselves to the limit, often neglecting their own well-being. As the world grapples with a confluence of challenges including the ongoing pandemic, climate crisis, and geopolitical tensions, the need for self-care becomes more pressing than ever.
Faculty
- Anna Saborowski (Moderator)
- Kelly Korreck (Faculty)
- Maria Panagioti (Faculty)
- Dina Tiniakos (Faculty)
Related Nature article by participant Kelly Korreck: How I managed my intense burnout
This episode is scheduled according to the international calendar for the World Mental Health Day (10 October).All EASL Studio Podcasts are available on EASL Campus.
In this episode, the discussants examines the following questions, raised after a Journal of Hepatology’s nomenclature article:
- Is the introduction of metabolic risk factors (MRF) for the definition of MASLD justified?
- What are the main issues regarding the measurement and thresholds for MRFs?
- Is the introduction of the MetALD category clinically justified?
- Is it necessary to worry about MRFs in a patient drinking increased or excessive amounts of alcohol and if yes, how should these be accounted for in disease classification systems?
Faculty
- Vlad Ratziu (Moderator)
- Giulio Marchesini (Faculty)
- Nancy Reau (Faculty)
- Roberto Vettor (Faculty)
Related article
- A multi-society Delphi consensus statement on new fatty liver disease nomenclature
Related episodes
- EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
All EASL Studio Podcasts are available on EASL Campus.
This EASL Studio episode covers the highlights of the SLD Summit 2023, including:
- Physiopathological mechanism
- Problems encountered in the cirrhotic stage in SLD
- Novelties about liver biopsies
Faculty
- Sven Francque (Moderator)
- Quentin Anstee (Faculty)
- Frank Tacke (Faculty)
- Maja Thiele (Faculty)
Related episodes
- EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways
- EASL Studio Live from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
- EASL Studio S4E23: The conundrum of NASH: The growing global disease burden with low disease awareness
- EASL Studio S4E22: JHEP Live: New and promising drugs for NASH on the horizon
All EASL Studio Podcasts are available on EASL Campus.
Hepatitis E is an inflammation of the liver caused by infection with the hepatitis E virus (HEV). HEV infections are among the most common causes of acute hepatitis worldwide.
2 different settings:
- HEV genotypes 1 and 2 cause primarily in water-born outbreaks inn resource-limited settings
- HEV genotypes 3 and 4 have emerged as porcine zoonoses in middle and high-income areas, including Europe
This Studio focuses on Zoonotic Hep E, especially HEV Genotype 3 infection and discusses recent highlights as well as current challenges in basic, translational, and clinical research on Hepatitis E.
Learn more about the viral and host determinants for the diverse clinical outcomes of HEV genotype 3 infections, the challenge of chronic Hepatitis E in immunocompromised patients, as well as the current state of vaccine development and other preventive measures.
Faculty
- Darius Moradpour (Moderator)
- Patrick Behrendt (Faculty)
- Montserrat Fraga Christinet (Faculty)
- Eike Steinmann (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Thirty percent of the global population have too much fat in their liver. The big question is: are they really sick when most will not end up with liver disease?
This episode discusses:
- How should they be assessed and by whom?
- What does this mean to healthcare systems?
- Are there downsides to systematic screening?
Faculty
- Aleksander Krag (Moderator)
- Alina Allen (Faculty)
- Manal El-Sayed (Faculty)
- Ian Rowe (Faculty
Related episode
- EASL Studio Live from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
All EASL Studio Podcasts are available on EASL Campus.
This #EASLStudio JHEP Live discusses the newly released EASL Clinical Practice Guidelines on Acute-on-chronic liver failure (ACLF).
In particular:
- ICU admission criteria for patients with ACLF
- Treatment of infection and antibiotic selection
- Liver support
- Liver transplantation for ACLF: Sarcopenia and frailty
Faculty
- Richard Moreau (Moderator)
- Rajiv Jalan (Faculty)
- Constantine Karvellas (Faculty)
- Rakhi Maiwall (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and is presenting the work of international liver societies to beat liver diseases.
Faculty
- Thomas Berg, EASL (Moderator)
- Marcelo Silva, ALEH (Faculty)
- Norah Terrault, AASLD (Faculty)
- Manal El-Sayed, SOLDA (Faculty)
- Shiina Shuichiro, APASL (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and discusses the newly released EASL policy statement on alcohol harm and related liver diseases. The document aims to highlight the extensive harm resulting from alcohol consumption and shine a light on the effective, yet underused, harm reduction policies available to European countries.
Faculty
- Frank Murray Ireland (Moderator)
- Maria Buti (Moderator)
- Thomas Babor (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
This EASL Studio Closing was live broadcast during the EASL Congress 2023 and discusses the future of hepatology.
Faculty
- Thomas Berg (Moderator)
- Aleksander Krag (Moderator)
- Tobias Böttler (Faculty)
- Debbie Shawcross (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
This EASL Studio Good Morning Vienna was live broadcast during the EASL Congress 2023 and is presenting the highlights of liver cancer research at the congress.
Faculty
- Jean-Charles Nault (Moderator)
- Josep Llovet (Moderator)
- Jessica Zucman-Rossi (Faculty)
- Bruno Sangro (Faculty)
- Matthias Pinter (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and discusses the nomenclature change for steatotic liver disease.
Faculty
- Aleksander Krag, EASL (Moderator)
- Philip Newsome, EASL (Faculty)
- Maru Rinella, AASLD (Faculty)
- Graciela Castro-Narro, ALEH (Faculty)
- Mohamed El-Kassas, SOLDA (Faculty)
- Robert Mitchell-Thain, LPI (Faculty)
- Lorraine Stiehl, ALF (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and is covering practice changing following data presented during the congress.
Faculty
- Virginia Hernández-Gea (Moderator)
- Ahmed Elsharkawy (Moderator)
- Maru Rinella (Faculty)
- Maria Reig (Faculty)
- Nancy Reau (Faculty)
- Verena Keitel (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
In honour of International NASH Day, the final episode of EASL Studio season 4 is shedding light on non-alcoholic steatohepatitis (NASH), a disease with increasing global prevalence but low awareness.
Faculty
- Zobair Younossi (Moderator)
- Alina M. Allen (Faculty)
- Sven Francque (Faculty)
- Vincent Wong (Faculty)
- Shira Zelber-Sagi (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Non-alcoholic steatohepatitis (NASH) is rapidly emerging as a leading cause of chronic liver disease, presenting significant challenge due to the limited treatment options available.
This EASL Studio JHEP Live aims to explore novel and promising treatments currently being evaluated for the treatment of NASH. In particular:
- ARO-HSD, an HSD17β13 inhibitor.
- PXL065 under evaluation in the DESTINY-1 trial.
- The investigation of an FXR agonist in fibrotic NASH as part of the LIVIFY trial.
Faculty
- Prof. Vlad Ratziu (Moderator)
- Prof. Stephen Harrison (Faculty)
- Dr Rohit Loomba (Faculty)
- Dr Loey Lung-Yi Mak (Faculty)
Related articles
- A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
- Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
- Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
All EASL Studio Podcasts are available on EASL Campus.
Clinical evidence indicates that cigarette smoking negatively impacts the incidence and severity of fatty liver disease, fibrosis progression, hepatocellular carcinoma development, and the outcomes of patients with advanced liver disease. The underlying mechanisms are complex and involve different pathophysiological pathways including oxidative stress and oncogenic signals.
To coincide with World No Tobacco Day, 31 May, this EASL Studio discusses some of the pathophysiological mechanisms that drive the progression of liver disease and cancer risk in those who smoke.
Faculty
- Prof. William Alazawi (Moderator)
- Prof. Debbie Shawcross (Moderator)
- Prof. Ramon Bataller (Faculty)
- Prof. Vanessa Stadlbauer-Köllner (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Collaborations are key in achieving scientific progress. The European Horizon COST Actions provide great opportunities to build, grant, and/or participate in pan-European collaborations in multidisciplinary topics, including liver diseases.
This EASL Studio:
- Provides you with information about the COST Action programme.
- Discusses the structure of the drug-induced liver injury (DILI) and cholangiocarcinoma (CCA) working groups.
- Highlights the potential for collaborative work within this programme.
Faculty
- Prof. Jesús Bañales (Moderator)
- Prof. Raul Andrade (Faculty)
- Dr Chiara Braconi (Faculty)
- Prof. Vincenzo Cardinale (Faculty)
Related episodes
- S4E13: EASL-EF CLIF and EU Grants: Exploring novel mechanisms and treatment of chronic liver failure
- S4E2: YI Choice: How to build consortia and registries
All EASL Studio Podcasts are available on EASL Campus.
On 22 May 2023, policymakers, thought leaders, Permanent Mission Representatives to the UN, WHO staff, and people affected by liver disease will gather at the EASL Office in Geneva for the invitation-only event on the side-lines of the 76th World Health Assembly: “Together for Better Liver Health: Mobilising Action for Fatty Liver Disease”.* The aim of the event is to raise awareness on the need for action, and to call for a coordinated response to combat the global public health threat represented by fatty liver disease.
Fatty liver disease is the most prevalent liver disease in history, affecting over one in three adults globally and 10% of children. If left unchecked, it can progress to cirrhosis and liver cancer. Despite its prevalence, fatty liver disease remains largely unknown, and its burden is expected to grow further in the years ahead.
The episode showcases the collective effort of global stakeholders who stand united to advocate that fatty liver diseases are included in national and global policies. Our moderator, EASL Vice-Secretary Prof. Aleksander Krag, is joined by distinguished faculty members representing organisations from around the world.
Don’t miss this opportunity to learn about the strategies being put in place to promote liver health and the urgent need for coordinated approaches. Participate in this call for action to address fatty liver disease as a critical step toward a healthier future for all.
*The World Health Assembly is held annually and is an occasion for all WHO member delegations to discuss and make strides on global health issues. The EASL event builds upon WHA76 agenda item 11.2 which includes discussions on policy options and cost-effective interventions for the prevention and control of noncommunicable disease (NCDs). By raising the profile of fatty liver disease, the EASL’s event on the side-lines of the WHA and the publicly accessible EASL Studio special episode can help to catalyse action and improve liver health outcomes worldwide.
Faculty
- Prof. Aleksander Krag (Moderator)
- Prof. Ajay Duseja (Faculty)
- Prof. Manal El-Sayed (Faculty)
- Mr. Marko Korenjak (Faculty)
- Prof. Mario Pessoa (Faculty)
- Prof. Mary E. Rinella (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Hepatitis D is the most severe form of viral hepatitis infection, but fortunately, new treatments are on the horizon.
This EASL Studio discusses:
- Which patients should be treated.
- Currently available treatment options.
- Treatment combinations and duration.
- New treatments in development.
Faculty
- Prof. Heiner Wedemeyer (Moderator)
- Prof. Soo Aleman (Faculty)
- Prof. Pietro Lampertico (Faculty)
Related episodes:
- S2E3: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitor.
- S2E8: Treatment of HBV-HDV coinfection in the era of entry inhibition.
- Midday Talks: HBV and HDV drug development – Where do we stand and where are we going?
All EASL Studio Podcasts are available on EASL Campus.
International Nurses Day, 12 May, commemorates the birth of Florence Nightingale, considered to be the founder of modern nursing.
EASL Studio is taking this opportunity to highlight the important role of nursing in the care of people with liver disease.
Faculty
- Dr Kathryn Jack (Moderator)
- Mrs Michelle Clayton (Faculty)
- Mrs Núria Fabrellas (Faculty)
- Mrs Denise Schäfer (Faculty)
- Dr Patrizia Künzler-Heule (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Although a longstanding recommendation, the use of albumin as an effective treatment for patients with cirrhosis and ascites has come under scrutiny with recently published studies creating confusion.
This EASL Studio discusses, recent results from the MACHT, ATTIRE and PRECIOSA studies and try to shed some light on this controversial topic.
Faculty
- Prof. Alastair O’Brien (Moderator)
- Prof. Aleksander Krag (Moderator)
- Prof. Paolo Caraceni (Faculty)
- Dr Elisa Pose (Faculty)
- Prof. Joan Clària (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Watch this EASL Studio for highlights from the Liver Cancer Summit 2023.
Discover:
- How artificial Intelligence is being used to increase knowledge in the field of liver cancer.
- New markers in hepatocellular carcinoma beyond ultrasound.
- Updates in the field cholangiocarcinoma and rare liver diseases
- … and much more!
Faculty
- Prof. Mathias Heikenwälder (Moderator)
- Prof. Josep Llovet (Faculty)
- Prof. Helen Reeves (Faculty)
Related episodes:
- S3E16 – Liver cancer in 2022: Wrap-up & outlook
- S2E15 – JHEP Live – The best animal model for HCC — lost in translation
- Special Edition: Highlights of the Liver Cancer Summit 2022
- Policy Dialogues Episode 3: Liver Cancer: The risk of ignorance
All EASL Studio Podcasts are available on EASL Campus.
Wilson’s disease is a rare autosomal recessive disorder of copper metabolism which is characterised by hepatic and neurological disease
This episode of EASL Studio will:
- Cover the difficulties in diagnosing Wilson’s disease.
- Discuss treatment options and strategies.
- Explore the challenges faced by patients with Wilson’s disease.
Faculty
- Prof. Emmanuel Tsochatzis (Moderator)
- Dr Wiebke Papenthin (Patient Perspective)
- Dr Aurélia Poujois (Faculty)
- Prof. Piotr Socha (Faculty)
Related episodes:
- S4E7 – Genetics in adult liver disease – missed opportunities?
- S3E10 – Cholestatic pruritus: Can the itch be ditched?
All EASL Studio Podcasts are available on EASL Campus.
The EASL Policy Statement on liver cancer screening has recently been updated.
In addition to addressing the updates, this episode of EASL Studio will discuss how risk-based surveillance of hepatocellular carcinoma (HCC) in patients suffering from cirrhosis is a cost effective strategy to increase benefits, reduce the harm of HCC surveillance.
Faculty
- Prof. Thomas Berg (Moderator)
- Mr. Pietro Fiocchi (Faculty)
- Prof. Peter Jepsen (Faculty)
- Mrs. José Willemse (Patient Perspective)
All EASL Studio Podcasts are available on EASL Campus.
Through widespread multidisciplinary collaboration, consortia and EU grants provide unique opportunities to address critical questions.
- What opportunities exist for early career scientist?
- Which elements are essential for success?
- How have these partnerships contributed to advancements in the field?
Watch this episode of EASL Studio to find out.
Faculty
- Prof. Thomas Berg (Moderator)
- Prof. Rajiv Jalan (Moderator)
- Prof. Minneke Coenraad (Faculty)
- Dr Cornelius Engelmann (Faculty)
- Prof. Pierre-Emmanuel Rautou (Faculty)
Related episode
- S4E2 YI Choice: How to build consortia and registries
All EASL Studio Podcasts are available on EASL Campus.
The topic of liver transplantation for alcohol-related hepatitis is controversial. While some experts still recommend 6 months of alcohol abstinence before considering transplantation others advocate for early transplantation.
Watch this episode to:
- Understand the epidemiology of alcohol-related hepatitis.
- Know which treatment options are available to these patients
- Find out which patients may benefit from earl liver transplantation.
Faculty
- Prof. Patrizia Burra (Moderator)
- Dr Giacomo Germani (Faculty)
- Prof. Alexandre Louvet (Faculty)
Related episodes
- S4E6 – Regenerating the liver graft with a machine
- S3E5 – JHEP Live: Stigma and alcohol
All EASL Studio Podcasts are available on EASL Campus.
Liver biopsy has long been the gold standard for diagnosing NAFLD and NASH. However, it is an invasive procedure that may not always be necessary. This episode of EASL Studio explored methods for screening, staging, and monitoring disease progression.
Faculty
- Prof. Philip Newsome (Moderator)
- Prof. Laurent Castera (Faculty)
- Prof. Maja Thiele (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Emerging therapeutics based on gene addition, editing, or silencing are expected to change the landscape of genetic liver disease.
Watch this episode to find out:
- Which approaches exist?
- Where are they in terms of preclinical and clinical development?
- How will they be used?
Faculty
- Dr Mattias Mandorfer (Moderator)
- Dr Gloria Gonzalez-Aseguinolaza (Faculty)
- Prof. Pavel Strnad (Faculty)
- Prof. Man-Fung Yuen (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Ascites is the final consequence in a series of anatomic, pathophysiologic, and biochemical abnormalities and one of the most common complications of advanced cirrhosis.
This EASL Studio will be discussing:
- Is it all about portal pressure?
- Which treatment option for which patient?
- Which trials are needed?
Faculty
- Prof. Thomas Reiberger (Moderator)
- Prof. Benjamin Maasoumy (Faculty)
- Prof. Virginia Hernández-Gea (Faculty)
- Prof. Cristina Ripoll (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
In honour of International Women’s day, this episode of EASL Studio will be raising awareness about the gender gap in academic research and debating how to improve gender diversity.
Faculty
- Dr Johanne Poisson (Moderator)
- Prof. Eric Trépo (Moderator)
- Prof. Dina Balabanova (Faculty)
- Dr Ea Høg Utoft (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Alcohol and food policies are increasingly being introduced to restrict marketing of and access to unhealthy foods.
- What impact will they have on consumption?
- How should they be implemented?
- How will they affect the incidence of liver and gastrointestinal diseases?
Tune in to find out.
Faculty
- Prof. Shira Zelber-Sagi (Moderator)
- Prof. Helena Cortez-Pinto (Faculty)
- Dr Sandro Demaio (Faculty)
- Prof. Jeffrey Lazarus (Faculty)
- Prof. Nick Sheron (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Machine perfusion is changing the status quo in liver transplantation by optimising the use of organs in times of organ shortage.
Watch this EASL Studio to:
- Better understand the role of machine perfusion in liver transplantation
- Understand the optimal situations in machine perfusion is beneficial
- Have an overview of the different types of machines under evaluation
Faculty
- Prof. Marina Berenguer (Moderator)
- Prof. Pierre-Alain Clavien (Faculty)
- Dr Amelia Hessheimer (Faculty)
Related episodes
- S3E8 – Transplanting patients with cancer – Is there a limit?
- S3E2 – Liver transplantation for ACLF: Opportunities, challenges, and pitfalls
All EASL Studio Podcasts are available on EASL Campus.
The field of artificial Intelligence (AI) is rapidly growing and derived technologies are technologies are increasingly being used in medical sciences to improve patient outcomes.
- What exactly is AI?
- How can it be beneficial?
- Why should AI be used in medicine?
Watch this EASL Studio to find out.
Faculty
- Prof. Jakob Nikolas Kather (Moderator)
- Prof. Julien Calderaro (Faculty)
- Dr Arsela Prelaj (Faculty)
- Dr Tobias Seraphin (Faculty)
- Dr Katy Wack (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Although there is an almost unanimous consensus on the prognostic weight of the term ‘decompensation’, a clear corresponding consensus on its definition is still lacking. In addition, classifying cirrhosis as compensated and decompensated oversimplifies the clinical course of the disease which encompasses many different groups.
Faculty
- Prof. Paolo Angeli (Moderator)
- Prof. Guadalupe Garcia-Tsao (Faculty)
- Prof. Salvatore Piano (Faculty)
- Prof. Thomas Reiberger (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Alcohol is the main cause of advanced liver disease and a major cause of hospitalisation and disability across the globe, including Europe. In this EASL Studio you will hear the patient perspective from an individual who has overcome this disease and listen to the faculty discuss the measures that can help prevent it.
Faculty
- Prof. Ramon Bataller (Moderator)
- Prof. Giovanni Addolorato (Faculty)
- Prof. Peter Jepsen (Faculty)
- Prof. Debbie Shawcross (Faculty)
- Mrs Kristen Radage (Faculty)
- Mr. Steven Rodrigues (Patient Perspective)
Related episodes
- S3E5: JHEP Live: Stigma and alcohol
- S3E4: Special Edition: Highlights of EASL NAFLD Summit 2022
All EASL Studio Podcasts are available on EASL Campus.
The value of scientific collaboration and data sharing through registries and consortia is unequivocal. But what are the main challenges to building a consortium and how do we overcome them.
Join the faculty as they provide you with a practical, experience-based view of how to build a successful consortium.
Faculty
- Dr Marta Afonso (Moderator)
- Dr Mattias Mandorfer (Moderator)
- Prof. Jesús Bañales (Faculty)
- Prof. Rajiv Jalan (Faculty)
- Prof. Pierre Emmanuel Rautou (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
In the first episode of EASL Studio season 4, the faculty looked at the current status of hepatitis B elimination and discussed what needs to be done to achieve it.
Faculty
- Dr Ahmed Elsharkawy (Moderator)
- Mr Danjuma K. Adda (Faculty)
- Prof. Maud Lemoine (Faculty)
- Prof. Jean-Michel Pawlotsky (Faculty)
- Dr John Ward (Faculty)
Related episodes
- Special Edition: Live from Viral Hepatitis Elimination Conference 2022
- S3E2: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitor
- S2E8: Treatment of HBV-HDV coinfection in the era of entry inhibition
All EASL Studio Podcasts are available on EASL Campus.
Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss:
- why certain trials have failed whereas others have succeeded,
- what we have learned about the connection between overall survival and progression-free survival as endpoints, and
- how the systemic therapy of HCC has evolved.
Faculty
- Prof. Peter Galle (Moderator)
- Prof. Bruno Sangro (Faculty)
- Dr Anna Saborowski (Faculty)
- Prof. Arndt Vogel (Faculty)
Related episodes
- S2E15 – JHEP Live – The best animal model for HCC — lost in translation
- Special Edition: Highlights of the Liver Cancer Summit 2022
- Policy Dialogues Episode 3: Liver Cancer: The risk of ignorance
All EASL Studio Podcasts are available on EASL Campus.
In this episode of EASL Studio the experts discuss a non-cirrhotic portal vein thrombosis (PVT):
- What is PVT in the absence of cirrhosis,
- The role of interventional radiology in the management of portal cavernoma, and
- An update from the VALDIG portal Vein Thrombosis meeting
Faculty
- Prof. Pierre-Emmanuel Rautou (Moderator)
- Prof. Juan-Carlos Garcia-Pagan (Faculty)
- Dr Aurélie Plessier (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
As we near the end of 2022, this EASL Studio reflects upon:
- Which topics were most published about
- Which fields will we focus on in 2023
- What will the future of hepatology look like?
Faculty
- Prof. Paolo Angeli (Moderator)
- Prof. Jessica Zucman-Rossi (Moderator)
- Prof. Thomas Berg (Faculty)
- Prof. Aleksander Krag (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Traditionally, journal impact factor has been the way to measure the impact of ones scientific articles. However, social media platforms are increasingly being used for the dissemination of publications. Join the faculty as they debate novel metrics to measure the impact of articles.
Faculty
- Prof. Jesus Banales (Moderator)
- Dr Atoosa Rabiee (Faculty)
- Dr Elliot Tapper (Faculty)
- Dr Juan Turnes (Faculty)
Related episode
- New era for science dissemination: The role of social media
All EASL Studio Podcasts are available on EASL Campus.
Antimicrobial resistance (AMR) is growing problem that greatly impacts treatment outcome. In this episode the faculty discuss:
- The impact of prescribing antibiotics as primary and secondary prophylaxis on AMR rates
- What can be done globally to reduce AMR rates
Faculty
- Prof. Debbie Shawcross (Moderator)
- Prof. Jonel Trebicka (Moderator)
- Prof. Jasmohan Bajaj (Faculty)
- Dr Lindsey Edwards (Faculty)
- Dr Benedikt Huttner (Faculty, WHO representative)
All EASL Studio Podcasts are available on EASL Campus.
Currently, the only established therapeutic option for end-stage liver disease is orthotopic liver transplantation. However, the paucity of donor organs limits this option to only a few patients. From liver stem cells to advanced tissue bioengineering, this episode of EASL Studio discusses regenerative hepatology techniques as an alternative treatment for patients.
Faculty
- Prof. Pedro Baptista (Moderator)
- Prof. Tobias Cantz (Faculty)
- Prof. Karen Piper Hanley (Faculty)
- Prof. Frederic Lemaigre (Faculty)
Related episode:
- YI Choice: Propelling liver cell biology into the third dimension
All EASL Studio Podcasts are available on EASL Campus.
In this JHEP Live the faculty discuss the use of antisense oligonucleotides and siRNAs in the treatment of chronic hepatitis B infections.
Faculty
- Prof. Joerg Petersen (Moderator)
- Prof. Maria Buti (Faculty)
- Prof. Man-Fung Yuen (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
Listen to this EASL Studio to find out:
- Which policies for prioritisation exist within a deceased donor liver allocation system?
- What is the impact of novel cancer therapies on the selection of patients with prior cancer?
Faculty
- Prof. Sherrie Bhoori (Moderator)
- Prof. Pål-Dag Line (Faculty)
- Prof. Vincenzo Mazzaferro (Faculty)
- Prof. Gonzalo Sapisochin (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
In recent years, the role of the gut microbiome in the development and severity of various diseases has come to light. In this episode, the experts examines:
- The role of microbiome in obesity.
- The role of microbiome in the transition from NAFLD to NASH.
- Practical solutions in microbiome medications.
Faculty
- Prof. Oren Shibolet (Moderator)
- Dr Aleksandra Kolodziejczyk(Faculty)
- Prof. Eran Elinav (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
In honour of World Hospice and Palliative Care Day (8 October), this EASL Studio episode examines:
- When is the best time to think about end-of-life care in liver disease?
- What does it mean for the liver care team?
- When and how should patients be referred to specialised palliative care?
Faculty
- Dr Patrizia Künzler-Heule (Moderator)
- Prof. Philip Larkin (Faculty)
- Dr Philip Berry (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
People suffering from alcohol-related liver (ALD) disorders are subject to several forms of stigma. If not addressed, stigma may lead towards unfavourable health outcomes. This JHEP Live – based on a recent review – discusses:
- What forms of stigma do people suffering from ALD face?
- How does stigma affect them?
- What can be done about it?
ℹ️ Read this article for more information: G. Schomerus et al. The stigma of alcohol-related liver disease and its impact on healthcare Journal of Hepatology 2022 vol. 77 : 516–524
Faculty
- Prof. Patrizia Burra (Moderator)
- Prof. Georg Schomerus (Moderator)
- Dr Patrizia Carrieri (Faculty)
- Prof. Philippe Mathurin (Faculty)
All EASL Studio Podcasts are available on EASL Campus.
This episode of EASL Studio discusses the latest data in the treatment of NAFLD presented at the EASL NAFLD Summit 2022.
All EASL Studio Podcasts are available on EASL Campus.
This EASL Studio discusses important issues related to the opportunities and challenges of liver transplantation in acute-on-chronic liver failure (ACLF).
- Does urgent liver transplantation improve the survival of patients with ACLF-3 and where are the limits?
- Are the current allocation systems adequate and how to implement ACLF criteria for prioritisation?
- The distinct lack of equity of access of ACLF-3 patients to liver transplantation: Where are the barriers?
- What data will the CHANCE study deliver to address some of the unanswered questions?
All EASL Studio Podcasts are available on EASL Campus.
Several recent reports have postulated a link between autoimmune hepatitis (AIH) following SARS-CoV-2 infection or vaccination. This EASL Studio JHEP Live discuss the potential links between COVID-19 and AIH.
ℹ️ More information on the topic can be found in these articles:
- Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care, Rüther et al.,J Hepatol. 2022 Jul; 77(1): 250–251
- SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis, Böttler et al., J Hepatol. 2022 Apr 21
All EASL Studio Podcasts are available on EASL Campus.
This is the audio version of an episode that was originally broadcast live from The International Liver Congress 2022.
Discover all the EASL Studio episodes at ILC 2022 here.
This is the audio version of an episode that was originally broadcast live from The International Liver Congress 2022.
Discover all the EASL Studio episodes at ILC 2022 here.
This is the audio version of an episode that was originally broadcast live from The International Liver Congress 2022.
Discover all the EASL Studio episodes at ILC 2022 here.
This is the audio version of an episode that was originally broadcast live from The International Liver Congress 2022.
Discover all the EASL Studio episodes at ILC 2022 here.
This is the audio version of an episode that was originally broadcast live from The International Liver Congress 2022.
Discover all the EASL Studio episodes at ILC 2022 here.
Issues of climate change, global warming and sustainability are taking centre stage in political agendas across the globe, causing major restructuring in many sectors. But, what about the healthcare sector?
- How is climate change affecting healthcare?
- How big of a problem is climate change for liver care?
- What public health strategies can be implemented to mitigate the effects of climate change?
You can find more information about the impact of climate change on liver disease care in this publication.
Related podcast episodes:
EASL Studio Podcast S2E12: Nurse and AHP Focus: Sustainable Hepatology – Insights in nursing initiatives
All EASL Studio Podcasts are available on EASL Campus.
In honour of World Haemochromatosis week (1-7 June 2022) the newly updated EASL Clinical Practice Guidelines on Haemochromatosis will be discussed in this episode of EASL Studio.
Read more
All EASL Studio Podcasts are available on EASL Campus.
Mouse models, based on dietary, chemical or genetic interventions, are designed to serve as tools to understand human liver diseases.
With the number of models increasing:
- What types of models exist for hepatocellular carcinoma?
- How close do they mirror human liver cancer (subtypes)?
- Can they be used to predict therapeutic response?
- What are the best models? For which questions?
- From idea to conception, are we getting lost in translation?
Read this recent Journal of Hepatology article, on which the discussion was be based.
In the assessment of disease stage, liver pathology is still largely based on semi-quantitative methods. Recent advances in whole slide imaging have opened the door for the use of artificial intelligence (AI) and the creation of machine learning (ML) algorithms.
- What exactly is digital pathology?
- How can it be implemented in different disease areas?
- Can it be used in routine clinical practice?
In honour of the International Nurse Day (12 May), and to discuss sustainability in liver care, this week we will gain some insights into the impact of nursing initiatives.
- What is sustainable liver care?
- What role do nurses currently play?
- What current nurse-driven activities are promoting a sustainable clinical practice?
Read more: https://easlcampus.eu/videos/easl-studio-s2-e12-nurse-and-ahp-focus-sustainable-hepatology-insights-nursing-initiatives
Reduce, Refine, Replace. Developed over 50 years ago, the 3Rs provide a framework that urges researchers to think carefully about methods used to investigate scientific questions. In this episode of EASL Studio, we took a closer look at the third R, Replace. With the World Day for Laboratory Animals fast approaching, we discussed how to propel liver cell biology into the third dimension.
- What are the advantages of 3D cultures?
- Can liver cell types be studied in representative manner using 3D cultures?
- More importantly, which part of animal research can be replaced by 3D cell culture experiments?
This and more in EASL Studio: YI Choice.
Read more: https://easlcampus.eu/videos/easl-studio-s2-e9-yi-choice-propelling-liver-cell-biology-third-dimension
In recent years social media has become a powerful tool, not only for science dissemination, but also for discussing data and networking.
- What is the impact of dissemination via social media?
- How is social media changing the way data is communicated?
- Should social media activity be considered a professional endeavour?
Listen to this podcast to find out.
Read more: https://easlcampus.eu/podcasts/easl-studio-podcast-s2-e5-new-era-science-dissemination-role-social-media
Discover this EASL Studio Podcast highlighting the recently published EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. Join the faculty as they discuss:
- What effects do anticoagulants have on survival and liver related events in cirrhosis?
- What are the mechanisms of action?
- What type of anticoagulants should be used in patients with cirrhosis?
Read more: https://easlcampus.eu/podcasts/easl-studio-podcast-s2-e6-should-anticoagulants-be-given-patients-cirrhosis-improve-outcome
Discover this EASL Studio podcast discussing the Baveno Consensus started over 30 years ago with the aim of reviewing current diagnostic and therapeutic strategies and producing updated definitions.
But, with the extension of indication of non-steroidal beta blockers, has the consensus gone too far?
- Is there enough evidence for their use in already decompensated patients?
- How safe are they in this patient population?
- What do we know about the effects on refractory ascites? Circulatory dysfunction?
In this podcast conducted on the occasion of liver cancer awareness month, Dr. Massimo A. Iavarone, hepatologist at the Ospedale Maggiore in Milan, Italy, is answering key questions on liver cancer raised by the Liver Patients International (LPI) and PSC Support, two EASL-affiliated patient associations, both part of the EASL patient synergies project.
In this episode, Professor Markus Cornberg is joined by Dr Christiane Eberhardt and Professor Daniel Shouval to answer a range of questions raised by EASL’s Patient Synergies regarding the recently approved COVID-19 vaccinations.
They address topics including the reasons for the rapid development of the vaccines, whether immunocompromised liver transplant patients should receive the vaccine, real-world data from vaccination programmes worldwide and the potential duration of immunity.
Discover on our website more educational materials on COVID-19 and the liver.